These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 36591219)

  • 1. Immune-based combination therapy for esophageal cancer.
    Wang H; Xu Y; Zuo F; Liu J; Yang J
    Front Immunol; 2022; 13():1020290. PubMed ID: 36591219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising immunotherapies for esophageal cancer.
    Tanaka T; Nakamura J; Noshiro H
    Expert Opin Biol Ther; 2017 Jun; 17(6):723-733. PubMed ID: 28366014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Immunotherapy in Advanced Gastroesophageal Cancer.
    Terrero G; Lockhart AC
    Curr Oncol Rep; 2020 Aug; 22(11):112. PubMed ID: 32803457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in targeted therapy and immunotherapy for esophageal cancer.
    Yang H; Li X; Yang W
    Chin Med J (Engl); 2023 Aug; 136(16):1910-1922. PubMed ID: 37403208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Treatment Options in Metastatic Esophageal Carcinoma: Checkpoint Inhibitors in Combination Therapies.
    Casari C; Novysedlak R; Vachtenheim J; Lischke R; Strizova Z
    Pharmacology; 2023; 108(1):37-46. PubMed ID: 36463853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy.
    Ma Y; Yu J; Ma X; Li Q; Su Q; Cao B
    Asia Pac J Clin Oncol; 2024 Apr; 20(2):180-187. PubMed ID: 37171038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.
    Park R; Williamson S; Kasi A; Saeed A
    Anticancer Res; 2018 Oct; 38(10):5569-5580. PubMed ID: 30275174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer.
    Yang J; Janjigian YY
    Thorac Surg Clin; 2022 Nov; 32(4):467-478. PubMed ID: 36266034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
    Kadono T; Yamamoto S; Kato K
    Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of cancer immunotherapy for esophageal squamous cell carcinoma.
    Kono K; Mimura K; Yamada R; Ujiie D; Hayase S; Tada T; Hanayama H; Min AKT; Shibata M; Momma T; Saze Z; Ohki S
    Esophagus; 2018 Jan; 15(1):1-9. PubMed ID: 29892809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for esophageal cancer: a 2019 update.
    Schizas D; Charalampakis N; Kole C; Mylonas KS; Katsaros I; Zhao M; Ajani JA; Psyrri A; Karamouzis MV; Liakakos T
    Immunotherapy; 2020 Feb; 12(3):203-218. PubMed ID: 32208794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immune landscape of esophageal cancer.
    Huang TX; Fu L
    Cancer Commun (Lond); 2019 Nov; 39(1):79. PubMed ID: 31771653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives.
    Sardaro A; Ferrari C; Carbonara R; Altini C; Lavelli V; Rubini G
    Cancer Biother Radiopharm; 2021 Mar; 36(2):123-132. PubMed ID: 32551915
    [No Abstract]   [Full Text] [Related]  

  • 14. Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula.
    He L; Han Q; Zhao M; Ma H; Cheng P; Yang H; Zhao Y
    Appl Radiat Isot; 2024 Mar; 205():111162. PubMed ID: 38142544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tsunami of immunotherapies in the management of esophageal cancer.
    Kassab J; Saba L; Kassab R; Kourie HR
    Immunotherapy; 2022 Aug; 14(11):879-884. PubMed ID: 35703028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current status and prognosis of immune checkpoint inhibitors for esophageal cancer].
    Gao HJ; Shang XB; Yu ZT
    Zhonghua Wai Ke Za Zhi; 2019 Oct; 57(10):77-82. PubMed ID: 31510736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic Approaches to Biliary Cancer.
    Shah UA; Nandikolla AG; Rajdev L
    Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basis for molecular diagnostics and immunotherapy for esophageal cancer.
    Abdo J; Agrawal DK; Mittal SK
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):33-45. PubMed ID: 27838937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immuno-oncology for esophageal cancer.
    Yamamoto S; Kato K
    Future Oncol; 2020 Nov; 16(32):2673-2681. PubMed ID: 32777942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Immunotherapy and Lung Cancer.
    Sánchez de Cos Escuín J
    Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.